Through the current study, we offer a likely advantage of applying Slit3 to inhibit β-catenin pathway as a novel treatment strategy in HCC; since Slit3 is a naturally existing protein and this might reduce the occurrence of unexpected side-effects. Here, SLIT3 is linked to hepatocellular carcinoma.